Last updated on May 2018

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Brief description of study

The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open label, dose-escalating study. Each dose cohort will be concluded by a safety review, following which escalation to the next dose cohort will be approved.

Clinical Study Identifier: NCT02418793

Contact Investigators or Research Sites near you

Start Over

Miguel Escobar

The Gulf States Hemophilia and Thrombophilia Center
Houston, TX United States
  Connect »